Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Ratner, Lee ^a   Harrington, William ^b   Feng, Xuan ^a   Grant, Christian ^c   Jacobson, Steve ^c   Noy, Ariela ^d   Sparano, Joseph ^e   Lee, Jeanette ^f,i   Ambinder, Richard ^g   Campbell, Nancy ^a   Lairmore, Michael ^h  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF ARKANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; PENTAMIDINE; PREDNISONE; VINCRISTINE; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; REMISSION; T CELL LYMPHOMA; VIRUS EXPRESSION; VIRUS REACTIVATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84887212537     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004420     Document Type: Article

References (39)

1. Matsuoka M, Jeang K-T (2007) Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nature Reviews in Cancer 7: 270-80.
2. Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL (2005) Global epidemiology of HTLV-I and associated diseases. Oncogene 24: 6058-68.
3. Sun S-C, Yamaoka S (2005) Activation of NF-B by HTLV-I and implications for cell transformation. Oncogene 24: 5952-64.
4. Taylor GP, Matsuoka M (2005) Natural history of adult T-cell leukemia/ lymphoma and approaches to therapy. Oncogene 24: 6047-57.
5. Ratner L (2004) Adult T cell leukemia lymphoma. Frontiers in Biosciences 9: 2852-9.
6. Shimoyama M (1991) Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma: a report from the Lymphoma Study Group. British Journal of Hematology 79: 426-7.
7. Kamihira S, Sohda H, Atogami S, et al. (1992) Phenotypic diversity and prognosis of adult T-cell leukemia. Leukemia Research 16: 435-41.
8. Yano H, Ishida T, Inagaki A, et al. (2007) Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. International Journal of Cancer 120: 2052-7.
9. Abe M, Uchihashi K, Kazuto T, et al. (2008) Foxp3 expression on normal and leukemic CD4(+)CD25(+) T cells implicated in human T-cell leukemia virus type-1 is inconsistent with Treg cells. European Journal of Hematology 81: 209-17.
10. Shimauchi T, Kabashima K, Tokura Y (2008) Adult T-cell leukemia/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells. Cancer Science 2008; 99: 98-106.
11. Morton LM, Turner JJ, Cerhan JR, et al. (2007) Proposed classification of lymphoid neoplasms for epidemiologic research from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 110: 695-708.
12. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: World Health Organization Classification of Tumours.
13. Bazarbachi A, Ghez D, Lepelletier Y, et al. (2004) New therapeutic approaches for adult T-cell leukaemia. Lancet Oncology 5: 664-72.
14. Little RF, Pittaluga S, Grant N, et al. (2003) Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 101: 4653-9.
15. Wilson WH, Grossbard ML, Pittaluga S, et al. (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 99: 2685-93.
16. Gill PS, Harrington W, Kaplan MH, et al. (1995) Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332: 1744-8.
17. Hermine O, Bouscary D, Gessain A, et al. (1995) Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332: 1749-51.
18. Taylor GP, Hall SE, Navarrete S, et al. (1999) Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T cell phenotype, and anti-Tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol 73: 10289-95.
19. Cheson BD, Horning SJ, Coiffier B, et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology 17: 1244-53.
20. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clinical Trials 10: 1-10.
21. Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S (2001) Incrased activated human T celll ymphotropic virus type I (HTLV-I) Tax 11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associatd myelopathy/tropical spastic paraparesis: Correlation with HTLV-I proviral load. Journal of Infectious Diseases 183: 197-205.
22. Yamano Y, Nagai M, Brennan M, et al. (2002) Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8+ T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood 99: 88-94.
23. Sehn LH, Berry B, Chanabhai M, et al. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109: 1857-61.
24. Yamada Y, Tomonaga M, Fukuda H, et al. (2001) A new G-CSF supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. British Journal of Hematology 113: 375-82.
25. Mortreux F, Gabet AS, Wattel E (2003) Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia 17: 26-38.
26. Furukawa Y, Kubota R, Tara M, Izumo S, Osame M (2001) Existence of escape mutant in HTLV-1 tax during the development of adult T-cell leukemia. Blood 97: 987-93.
27. Furukawa R, Osame M, Kubota R, Tara M, Yoshida M. Human (1995) T-cell leukemia virus type-1 (HTLV-1) Tax is expressed at the same level in infected cells of HTLV-1-associated myelopathy or tropical spastic paraparesis patients as in asymptomatic carriers but at a lower level in adult T-cell leukemia cells. Blood 85: 1865-70.
28. Koiwa T, Hamano-Usami A, Ishida T, et al. (2002) 5′-Long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo. Journal of Virology 76: 9389-97.
29. Miller V, Larder BA (2001) Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antiviral Therapy 6 (Supplement 3): 25-44.
30. Furukawa Y, Tara M, Izumo S, Arimura K, Osame M (2006) HTLV-I viral escape and host genetic changes in the development of adult T cell leukemia. International Journal of Cancer 118: 381-7.
31. Iga M, Okayama A, Stuver S, et al. (2002) Genetic evidence of transmission of human T cell lymphotropic virus tyep 1 between spouses. Journal of Infectious Diseases 185: 691-5.
32. Major ME, Nightingale S, Dessleberger U (1993) Complete sequence conservation of the human T cell leukaemia virus type 1 tax gene within a family cluster showing differnet pathologies. Journal of General Virology 74: 2531-7.
33. Lin HC, Hickey M, Hsu L, Medina D, Rabson AB (2005) Activation of human T cell leukemia virus type 1 LTR promoter and cellular promoter elements by T cell receptor signaling and HTLV-1 Tax expression. Virology 339: 1-11.
34. Yamada Y, Kamihira S (2005) Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma. Leukemia Lymphoma 46: 1553-9.
35. Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC (2006) Proteasome inhibition as a new therapeutic principle in hematological malignancies. Current Drug Targets 7: 1341-7.
36. Horie R, Watanabe T, Umezawa K (2006) Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma. Drug News Perspectives 19: 201-9.
37. Vassilev LT (2007) MDM2 inhibitors for cancer therapy. Trends in Molecular Medicine 13: 23-31.
38. Waldmann TA, Morris JC (2006) Development of antibodies and chimeric molecules for cancer immunotherapy. Advances in Immunology 90: 83-131.
39. Kato K, Kanda Y, Eto T, et al. (2007) Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transplant 13: 90-9.